ClinicalTrials.govpublic full text
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian carcinoma, platinum-resistant primary peritoneal carcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, refractory fallopian tube carcinoma, refractory ovarian carcinoma, refractory primary peritoneal carcinoma, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 905980
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.